CCL2 and neoplasm: In contrast, a phase 1 trial (NCT00537368) of a human IgG1k monoclonal antibody which binds CCL2, carlumab, also known as CNTO888, in patients with advanced solid tumors refractory to conventional treatments showed no objective anti-tumor response in any of the 44 patients enrolled60.